X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1108) 1108
science & technology (1043) 1043
life sciences & biomedicine (1033) 1033
diabetes mellitus, type 2 - drug therapy (796) 796
type 2 diabetes (613) 613
endocrinology & metabolism (539) 539
hypoglycemic agents - therapeutic use (534) 534
diabetes (507) 507
male (450) 450
female (409) 409
hypoglycemic agents - adverse effects (375) 375
incretins - therapeutic use (370) 370
middle aged (320) 320
treatment outcome (302) 302
glucose (293) 293
dipeptidyl-peptidase iv inhibitors - therapeutic use (273) 273
incretin (272) 272
animals (268) 268
insulin (262) 262
incretins (261) 261
diabetes mellitus, type 2 - blood (253) 253
adult (239) 239
blood glucose - metabolism (238) 238
incretins - adverse effects (236) 236
aged (234) 234
glucagon (229) 229
hypoglycemic agents - administration & dosage (221) 221
blood glucose - drug effects (204) 204
liraglutide (196) 196
dextrose (191) 191
diabetes mellitus (191) 191
risk factors (184) 184
diabetes therapy (182) 182
hypoglycemic agents (180) 180
pharmacology & pharmacy (179) 179
peptides (171) 171
drug therapy (168) 168
care and treatment (166) 166
glp-1 (166) 166
glucagon-like peptide 1 - analogs & derivatives (161) 161
exenatide (160) 160
general & internal medicine (160) 160
internal medicine (160) 160
dipeptidyl-peptidase iv inhibitors - adverse effects (154) 154
diabetes mellitus, type 2 - complications (149) 149
drug therapy, combination (147) 147
glucagon-like peptide 1 - therapeutic use (145) 145
medicine, general & internal (144) 144
hypoglycemic agents - pharmacology (142) 142
obesity (141) 141
type 2 diabetes mellitus (135) 135
analysis (131) 131
clinical trials (129) 129
double-blind method (126) 126
incretins - metabolism (126) 126
incretins - administration & dosage (125) 125
medicine & public health (124) 124
peptides - therapeutic use (123) 123
diabetes mellitus, type 2 - metabolism (121) 121
health aspects (121) 121
insulin resistance (121) 121
glucagon-like peptide-1 receptor (118) 118
review (117) 117
abridged index medicus (116) 116
diabetes mellitus, type 2 - physiopathology (116) 116
glucagon-like peptide-1 (116) 116
hypoglycemia (115) 115
glycated hemoglobin a - metabolism (113) 113
research (109) 109
venoms - therapeutic use (109) 109
insulin - metabolism (107) 107
sitagliptin (107) 107
glucagon-like peptide-1 receptor - agonists (106) 106
cardiovascular system & cardiology (103) 103
metformin - therapeutic use (103) 103
receptors, glucagon - agonists (99) 99
hyperglycemia (98) 98
glucagon-like peptide 1 (95) 95
glucagon-like peptide 1 - metabolism (95) 95
hypoglycemia - chemically induced (90) 90
incretin therapy (90) 90
insulin - blood (89) 89
metformin (89) 89
adamantane - analogs & derivatives (88) 88
cardiac & cardiovascular systems (86) 86
glycosylated hemoglobin (85) 85
insulin - therapeutic use (84) 84
dipeptidyl-peptidase iv inhibitors - pharmacology (83) 83
sitagliptin phosphate (83) 83
digestive, oral, and skin physiology (81) 81
insulin secretion (81) 81
time factors (81) 81
glucose metabolism (79) 79
physiological aspects (78) 78
clinical trials as topic (76) 76
dipeptidyl-peptidase iv inhibitors - administration & dosage (76) 76
endocrine system (76) 76
incretins - pharmacology (76) 76
peptides - adverse effects (75) 75
dpp-4 inhibitors (71) 71
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1369) 1369
Spanish (12) 12
German (10) 10
French (6) 6
Japanese (5) 5
Czech (4) 4
Korean (4) 4
Norwegian (3) 3
Hungarian (2) 2
Italian (2) 2
Portuguese (2) 2
Russian (2) 2
Danish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CA: a cancer journal for clinicians, ISSN 0007-9235, 06/2010, Volume 60, Issue 4, pp. 207 - 221
Journal Article
Endocrine, ISSN 1559-0100, 11/2016, Volume 57, Issue 3, pp. 464 - 473
To compare the effect of liraglutide, sitagliptin and insulin glargine added to standard therapy on left ventricular function in post-ischemic type-2 diabetes mellitus... 
Type 2 diabetes | Glucagon-like peptide-1 | Medicine & Public Health | Science, Humanities and Social Sciences, multidisciplinary | Left ventricular ejection fraction | Cardiac function | Internal Medicine | Diabetes | Chronic heart failure | Endocrinology | Liraglutide | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Metformin - therapeutic use | Diabetic Cardiomyopathies - drug therapy | Humans | Middle Aged | Heart Failure - physiopathology | Ventricular Dysfunction, Left - complications | Male | Heart Failure - blood | Diabetic Cardiomyopathies - physiopathology | Metformin - adverse effects | Cardiotonic Agents - therapeutic use | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Ventricular Dysfunction, Left - blood | Cardiotonic Agents - adverse effects | Female | Diabetic Cardiomyopathies - blood | Diabetes Mellitus, Type 2 - complications | Heart - physiopathology | Hypoglycemic Agents - therapeutic use | Heart Failure - complications | Hyperglycemia - prevention & control | Insulin Glargine - adverse effects | Sulfonylurea Compounds - therapeutic use | Insulin Glargine - therapeutic use | Stroke Volume - drug effects | Biomarkers - blood | Sulfonylurea Compounds - adverse effects | Ventricular Dysfunction, Left - physiopathology | Heart Failure - drug therapy | Diabetes Mellitus, Type 2 - blood | Pilot Projects | Ventricular Dysfunction, Left - drug therapy | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - therapeutic use | Heart - drug effects | Quality of Life | Sitagliptin Phosphate - therapeutic use | Aged | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Sitagliptin Phosphate - adverse effects | Heart failure | Usage | Care and treatment | Electrocardiogram | Electrocardiography | Dosage and administration | EKG | Stroke | Echocardiography | Diabetes mellitus | Insulin | Beta blockers | Quality of life | Walking | Ischemia | Sulfonylurea | Metformin | Ventricle | Heart diseases | Index Medicus
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 04/2017, Volume 19, Issue 4, pp. 524 - 536
..., with the primary goal of achieving individualized glycaemic targets whilst minimizing adverse effects, particularly weight gain and hypoglycaemia. Glucagon‐like peptide‐1... 
GLP‐1 analogue | type 2 diabetes | network meta‐analysis | systematic review | network meta-analysis | GLP-1 analogue | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Immunoglobulin Fc Fragments - administration & dosage | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Peptides - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Glucagon | Analysis | Diabetes therapy | Hypoglycemia | Diabetes | Systematic review | Evidence-based medicine | Index Medicus
Journal Article
Contemporary Clinical Trials, ISSN 1551-7144, 2011, Volume 32, Issue 3, pp. 324 - 332
... diabetes drugs [2] and more recently to recommend a risk assessment and mitigation strategy for rosiglitazone [3] . An immediate effect of the guidelines was a pathway... 
Hematology, Oncology and Palliative Medicine | Cardiovascular | Saxagliptin and liraglutide | Sitagliptin | Alogliptin | Vildagliptin | Insulin inhalation powder | Exenatide | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Triazoles - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | United States | Humans | Pyrrolidines - adverse effects | Allylamine - adverse effects | Randomized Controlled Trials as Topic - standards | Time Factors | Investigational New Drug Application - legislation & jurisprudence | Sitagliptin Phosphate | Incretins - chemistry | Colesevelam Hydrochloride | Incretins - physiology | United States Food and Drug Administration | Adamantane - adverse effects | Adamantane - analogs & derivatives | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Dipeptides - adverse effects | Allylamine - analogs & derivatives | Uracil - adverse effects | Piperidines - adverse effects | Pyrazines - adverse effects | Cardiovascular Diseases - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Liraglutide | Peptides - adverse effects | Practice Guidelines as Topic | Uracil - analogs & derivatives | Type 2 diabetes | Hypoglycemic agents | Drug therapy | Cardiovascular diseases | Drug approval | Risk factors | Diabetes therapy | Index Medicus
Journal Article
Nutrition, Metabolism and Cardiovascular Diseases, ISSN 0939-4753, 2014, Volume 24, Issue 12, pp. 1346 - 1353
Abstract Background and aims In Italy, the reimbursed use of incretin mimetics and incretin enhancers was subject to enrollment of patients into a web-based... 
Cardiovascular | Type 2 diabetes | Real clinical practice | Incretin-mimetics and incretin-enhancers | Monitoring registry | DPP4 inhibitors and GLP1 receptor agonists | Cardiac & Cardiovascular Systems | Endocrinology & Metabolism | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Nutrition & Dietetics | Science & Technology | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Body Weight | Metformin - therapeutic use | Humans | Middle Aged | Pyrazines - administration & dosage | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Pyrazines - therapeutic use | Drug Utilization | Peptides - administration & dosage | Diabetes Mellitus, Type 2 - epidemiology | Pyrrolidines - therapeutic use | Nitriles - administration & dosage | Monitoring, Physiologic | Hypoglycemic Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions | Adamantane - therapeutic use | Venoms - administration & dosage | Female | Registries | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Venoms - adverse effects | Pyrazines - adverse effects | Sex Factors | Venoms - therapeutic use | Italy - epidemiology | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Peptides - therapeutic use | Nitriles - therapeutic use | Diabetics | Safety and security measures | Glucagon | Index Medicus
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 08/2014, Volume 16, Issue 8, pp. 673 - 688
Journal Article